Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide Immunogenicity and Long-term Safety in IBS-C and CIC
NCT02590432Phase 4Completed
- Sponsor
- Forest Laboratories
- Start
- Nov 2015
- Primary completion
- Feb 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of linaclotide in irritable bowel syndrome (IBS), chronic idiopathic constipation (CIC), sponsored by Forest Laboratories. Started Nov 2015; status: completed.
02
Drugs
linaclotide
03
Conditions
irritable bowel syndrome (IBS)chronic idiopathic constipation (CIC)
Beyond the preview
Go deeper on NCT02590432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02590432.